SALINAS, Calif. Next Pharmaceuticals on Tuesday released the results of an open label study on Relora. The study was conducted at The LaValle Metabolic Institute in Cincinnati, Ohio among 1,291 participants who suffered from stress, sleeplessness and/or stress-related eating.
According to the survey, 91 percent of the subjects reported Relora helped them relax, 90 percent reported Relora helped them have a restful sleep and 86 percent reported Relora helped prevent stress-related eating.
"This study demonstrates that Relora can be a successful adjunct for individuals who experience stress and anxiety, or who turn to food when dealing with tension," stated Charles Kosmont, chief executive officer of Next Pharmaceuticals. "There are many methods to managing stress, and Dr. LaValle’s clinical study supports the fact that Relora is a natural, safe and effective approach with no toxic side effects."
Relora consists of a patented blend of Magnolia bark extract and a proprietary blend of Phellodendron bark extract developed by Next Pharmaceuticals for the dietary supplement and functional food and beverage industries. Dr. James LaValle, author of Cracking the Metabolic Code, was the principal investigator of the study.
The subjects rated the efficacy of Relora on a 5-point scale. The product was considered effective for stress, restful sleep and stress-related eating if the subject rated the product 3 or higher. This study was developed as an open label, single center, clinical trial involving a minimum of 500 subjects with mild to moderate stress. Dr. LaValle enrolled both male and female subjects in the study as appropriate from patients at his clinic.